WO1986003121A1 - Produit de recalcification des tissus - Google Patents

Produit de recalcification des tissus Download PDF

Info

Publication number
WO1986003121A1
WO1986003121A1 PCT/US1984/001948 US8401948W WO8603121A1 WO 1986003121 A1 WO1986003121 A1 WO 1986003121A1 US 8401948 W US8401948 W US 8401948W WO 8603121 A1 WO8603121 A1 WO 8603121A1
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
silica
recited
elemental
potassium
Prior art date
Application number
PCT/US1984/001948
Other languages
English (en)
Inventor
Stephen D. Sawruk
Original Assignee
Sawruk Stephen D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sawruk Stephen D filed Critical Sawruk Stephen D
Priority to PCT/US1984/001948 priority Critical patent/WO1986003121A1/fr
Priority to EP19850900341 priority patent/EP0202222A1/fr
Publication of WO1986003121A1 publication Critical patent/WO1986003121A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Definitions

  • This invention is concerned with a novel combination of organic nutrients which is highly useful in the re-calcifi ⁇ cation of calcium-depleted tissues and, in particular, which is useful in replacing the so-called cortical boney matrix of the bone that constitutes the middle layer in the structure of the bone.
  • Such calcium depletion is commonly caused by such phenomenon as aging., malnutrition, and injury to the bone per se.
  • the present invention comprises a combination of natur ⁇ ally occurring silica such as vegetal silica which includes the compound silicon dioxide; and commonly occurring potassium such as potassium gluconate, the Combination of which is in approximately equal parts.
  • the combination is employed as a dietary supplement; thereby; the resulting elemental potassium acts to promote absorption of the elemental silicon into the bloodstream.
  • the elemental silicon then, together with carbon derived from normal biological processes (the breakdown of carbohy ⁇ drates) , serves in a catalytic transmutational function in order to bring about the deposition of calcium into the areas
  • Mineral-containing mixtures in accordance with the pre ⁇ sent invention include a physical admixture of herbal silica and elemental potassium (K) .
  • her ⁇ bal silica is derived in the form of vegetal silica from the equisetum species of plant.
  • the chemical formula for the vegetal silica is the same as that for inorganic silicon di ⁇ oxide (Si0 2 ) •
  • elemental potassium in the form of potassium glu- conate. It is to be appreciated that there are other sources from which elemental potassium may be derived, e.g., potassium biocarbonate and other naturally occurring products such as kelp which is rich in elemental potassium. It is contemplated that equal quantities of vegetal sil and potassium gluconate will be mixed and sold as a dietary supplement, this mixture containing neither sugar, starch, artificial coloring nor pre ⁇ servatives.
  • Another ingredient that may be added is an analgesic.
  • the sole function of the elemental potassium is to promote the absorption of the silica into the bloodstream; that is, the only function of the potas ⁇ sium is to act as a carrier of the silica into the bloodstream.
  • the silica Once the silica has entered the bloodstream, it will separate into its components of silicon and oxygen. After this has occurred, the silicon will co-act with free carbon in the bloodstream (this carbon having been derived from normal met ⁇ abolic processes including the breakdown of hydrocarbons) in order to jointly act as a transmutational catalyst to enhance the formation of calcium within the bones and, as noted, to particularly enhance the re-calcification of the comical boney matrix (the middle layer) of the bones.
  • a combination of free silicon and carbon will serve as a cat ⁇ alyst to enable depleted bone tissue to become re-calcified.
  • the chemistry herein involved is essentially identical to that as which occurs in the formation of limestone as well ⁇ in certain organic processes including the formation of calcium within the shells of eggs of aieves (the bird family) .
  • silicon and carbon have been found to perform a useful catalytic function in the enhancement of calcium deposition in bones in the human body.
  • the selection of a 500 mg level for the vegetal silica and potassium gluconate is based upon established safe levels of said ingredients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un agent de recalcification agit sur des tissus osseux humains. L'agent de recalcification comprend un mélange de silice végétale et de gluconate de potassium.
PCT/US1984/001948 1984-11-27 1984-11-27 Produit de recalcification des tissus WO1986003121A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US1984/001948 WO1986003121A1 (fr) 1984-11-27 1984-11-27 Produit de recalcification des tissus
EP19850900341 EP0202222A1 (fr) 1984-11-27 1984-11-27 Produit de recalcification des tissus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1984/001948 WO1986003121A1 (fr) 1984-11-27 1984-11-27 Produit de recalcification des tissus

Publications (1)

Publication Number Publication Date
WO1986003121A1 true WO1986003121A1 (fr) 1986-06-05

Family

ID=22182344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1984/001948 WO1986003121A1 (fr) 1984-11-27 1984-11-27 Produit de recalcification des tissus

Country Status (2)

Country Link
EP (1) EP0202222A1 (fr)
WO (1) WO1986003121A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5035898A (en) * 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
EP0916270A2 (fr) * 1997-11-18 1999-05-19 EnergyBalance AG Mélange de minéraux dont le goût est amélioré

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1513298A (en) * 1923-01-11 1924-10-28 John W Turrentine Therapeutic product and process of preparing same
US4259315A (en) * 1980-06-13 1981-03-31 A. H. Robins Company, Inc. Controlled release potassium dosage form

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1513298A (en) * 1923-01-11 1924-10-28 John W Turrentine Therapeutic product and process of preparing same
US4259315A (en) * 1980-06-13 1981-03-31 A. H. Robins Company, Inc. Controlled release potassium dosage form

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5035898A (en) * 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
EP0916270A2 (fr) * 1997-11-18 1999-05-19 EnergyBalance AG Mélange de minéraux dont le goût est amélioré
EP0916270A3 (fr) * 1997-11-18 1999-12-08 EnergyBalance AG Mélange de minéraux dont le goût est amélioré

Also Published As

Publication number Publication date
EP0202222A1 (fr) 1986-11-26

Similar Documents

Publication Publication Date Title
Greenwood Fluoride intoxication
WO1994001006A2 (fr) Composition destinee a etre utilisee comme aliment ou comme complement alimentaire
US6867176B2 (en) Method for preparing zinc-oligopeptide easily absorbable by the human body
Draper et al. Nutrition and osteoporosis
WO1986003121A1 (fr) Produit de recalcification des tissus
JP3459932B2 (ja) 抗骨粗鬆症組成物
Pillai et al. Role of protozoa in the aerobic purification of sewage
GB2289219A (en) Hair growth compositions
JPH0853358A (ja) 吸収性に優れたカルシウム組成物
Givens STUDIES IN CALCIUM AND MAGNESIUM METABOLISM: IV. EXPERIMENTS ON MAN
RU2220737C1 (ru) Лечебно-профилактическая композиция "остеомакс экстра" для улучшения функционального состояния опорно-двигательного аппарата
JP3005794B2 (ja) 抗骨粗鬆症作用を発揮する骨量増進組成物
US5620709A (en) Calcium containing composition from sea urchin with high oral bioavailability
RU2030178C1 (ru) Адаптогенное средство
Deichmann et al. Pain in jawbones and teeth in ciguatera intoxications
RU2205648C1 (ru) Состав "кальцисан" для профилактики и поддерживающей терапии заболеваний желудочно-кишечного тракта
US20060165846A1 (en) Nutritional supplement containing honey
CN1392263A (zh) 用酶制备易于体内吸收的蛋白化－钙的方法及利用该种蛋白化－钙生产的保健食品
KR20210063539A (ko) 식이 유황을 함유하는 건강보조식품 및 그 제조방법
RU2018238C1 (ru) Безалкогольный напиток
RU2217141C1 (ru) Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
JP2003063970A (ja) 抗骨粗鬆症組成物
CN1210690A (zh) 补钙饮食和调味剂
Broadhurst Silicon’s elemental benefits
Norton Maritime Occupational Disease:“the Scurvy”

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP SE SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB LU NL SE